PMV Pharmaceuticals, Inc. (PMVP)
PMVP moved a median of 0.00% 30 minutes after news, and +0.62% by the close. How PMVP actually reacts to news — the realized, point-in-time move the market made, measured across 166 labeled events over the last three years with zero look-ahead.
PMVP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 162 |
| 30-min | 0.00% | 40% | 166 |
| 60-min | +0.37% | 54% | 166 |
| to close | +0.62% | 55% | 166 |
| Middle 50% of PMVP reactions | -1.71% to +1.81% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 166 |
Half of all PMV Pharmaceuticals, Inc. news events land between -1.71% and +1.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PMVP reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 11 | +0.80% | 73% | -0.93% |
| Rating reiterations | 16 | -0.02% | 50% | -0.39% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how PMVP ranks against every other measured name →
That’s how PMVP usually reacts — get an email when it moves on news →Email me when PMVP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PMVP's baseline. Nothing else.
Recent PMVP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K PMV Pharmaceuticals, For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +1.39% | -1.11% | |
| PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors | Press release | GlobeNewswire | +1.39% | -1.11% | |
| PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer | Press release | GlobeNewswire | +0.78% | +3.88% | |
| Form 8-K PMV Pharmaceuticals, For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +0.00% | |
| Form 8-K PMV Pharmaceuticals, For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +4.35% | +12.17% | |
| PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities | Press release | GlobeNewswire | +4.35% | +12.17% | |
| PMV Pharma Announces Proposed Public Offering of Securities | Press release | GlobeNewswire | +4.35% | +12.17% | |
| PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial | Press release | GlobeNewswire | +4.35% | +12.17% | |
| Form 10-Q PMV Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.44% | |
| Form 8-K PMV Pharmaceuticals, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.44% | |
| PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights | Press release | GlobeNewswire | +0.00% | +2.44% | |
| Form 8-K PMV Pharmaceuticals, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | -5.08% | |
| Form 10-Q PMV Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.69% | -1.39% | |
| Form 8-K PMV Pharmaceuticals, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | -1.39% | |
| PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -0.69% | -1.39% | |
| Form ARS PMV Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +1.37% | |
| Form DEF 14A PMV Pharmaceuticals, For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +1.37% | |
| Form DEFA14A PMV Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +1.37% | |
| PMV Pharmaceuticals Announces Board Chair Transition | Press release | GlobeNewswire | +0.00% | +1.37% | |
| Form 10-K PMV Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.63% | +0.61% | |
| Form 8-K PMV Pharmaceuticals, For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | +0.61% | |
| Form S-8 PMV Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +0.63% | +0.61% | |
| PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | +0.63% | +0.61% | |
| New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors | Press release | GlobeNewswire | -3.00% | +11.38% | |
| Form 10-Q PMV Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.22% | +5.18% | |
| Form 8-K PMV Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +2.22% | +5.18% | |
| PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | +2.22% | +5.18% | |
| PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation | Press release | GlobeNewswire | +0.00% | -0.64% | |
| PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Press release | GlobeNewswire | +2.31% | +9.23% | |
| Form 8-K PMV Pharmaceuticals, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -2.24% | |
| PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation | Press release | GlobeNewswire | -9.51% | -29.44% | |
| Form 10-Q PMV Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.34% | -2.69% | |
| Form 8-K PMV Pharmaceuticals, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | -2.69% | |
| PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -1.34% | -2.69% | |
| Form 8-K PMV Pharmaceuticals, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +2.80% | +6.00% | |
| PMV Pharmaceuticals to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.25% | -1.10% | |
| Form 10-Q PMV Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +3.85% | |
| Form 8-K PMV Pharmaceuticals, For: May 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.85% | |
| PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights | Press release | GlobeNewswire | +0.00% | +3.85% | |
| Form ARS PMV Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -1.89% | |
| Form DEF 14A PMV Pharmaceuticals, For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -1.89% | |
| Form DEFA14A PMV Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -1.89% | |
| Form 10-K PMV Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.21% | -2.94% | |
| Form 8-K PMV Pharmaceuticals, For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -2.21% | -2.94% | |
| PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -2.21% | -2.94% | |
| PMV Pharmaceuticals to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -0.71% | |
| Form S-8 PMV Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | — | +2.14% | |
| Form EFFECT PMV Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +1.26% | +1.89% | |
| Form S-3 PMV Pharmaceuticals, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -0.63% | |
| Form 10-Q PMV Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.60% | +7.23% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PMVP section they belong to.
Where else PMVP is measured.
PMVP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PMV Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled PMVP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 166 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of PMVP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PMVP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.